Roth Capital analyst Anton Brenner says that while adverse currency translation and a sales mix shift should adversely affect income comparisons in Q1, these short-term considerations should not undermine Neogen's extremely attractive outlook. The analyst expects that the implementation of the Food Safety Modernization Act and increasing food safety considerations in developing international markets will generate sustained double-digit revenue growth and improving profit margins over the next several years. He reiterates a Buy rating and $68 price target on Neogen's shares.